全文获取类型
收费全文 | 259340篇 |
免费 | 16021篇 |
国内免费 | 991篇 |
学科分类
医药卫生 | 276352篇 |
出版年
2023年 | 1651篇 |
2022年 | 1482篇 |
2021年 | 5964篇 |
2020年 | 4391篇 |
2019年 | 6081篇 |
2018年 | 7846篇 |
2017年 | 5964篇 |
2016年 | 6101篇 |
2015年 | 6911篇 |
2014年 | 9235篇 |
2013年 | 11950篇 |
2012年 | 18350篇 |
2011年 | 19035篇 |
2010年 | 10027篇 |
2009年 | 8878篇 |
2008年 | 15053篇 |
2007年 | 15674篇 |
2006年 | 14518篇 |
2005年 | 14499篇 |
2004年 | 13403篇 |
2003年 | 12202篇 |
2002年 | 9765篇 |
2001年 | 5431篇 |
2000年 | 5277篇 |
1999年 | 4817篇 |
1998年 | 1976篇 |
1997年 | 1635篇 |
1996年 | 1536篇 |
1995年 | 1512篇 |
1994年 | 1478篇 |
1993年 | 1298篇 |
1992年 | 2928篇 |
1991年 | 2763篇 |
1990年 | 2531篇 |
1989年 | 2517篇 |
1988年 | 2281篇 |
1987年 | 2089篇 |
1986年 | 1982篇 |
1985年 | 1874篇 |
1984年 | 1381篇 |
1983年 | 1127篇 |
1982年 | 712篇 |
1981年 | 619篇 |
1980年 | 605篇 |
1979年 | 995篇 |
1978年 | 680篇 |
1977年 | 534篇 |
1975年 | 587篇 |
1974年 | 587篇 |
1973年 | 569篇 |
排序方式: 共有10000条查询结果,搜索用时 125 毫秒
1.
Jos B. Poell Leon J. Wils Arjen Brink Ralf Dietrich Christine Krieg Eunike Velleuer Ilkay Evren Elisabeth R. Brouns Jan G. de Visscher Elisabeth Bloemena Bauke Ylstra Ruud H. Brakenhoff 《International journal of cancer. Journal international du cancer》2023,152(2):227-238
Oral squamous cell carcinomas (OSCCs) develop in genetically altered epithelium in the mucosal lining, also coined as fields, which are mostly not visible but occasionally present as white oral leukoplakia (OL) lesions. We developed a noninvasive genetic assay using next-generation sequencing (NGS) on brushed cells to detect the presence of genetically altered fields, including those that are not macroscopically visible. The assay demonstrated high accuracy in OL patients when brush samples were compared with biopsies as gold standard. In a cohort of Fanconi anemia patients, detection of mutations in prospectively collected oral brushes predicted oral cancer also when visible abnormalities were absent. We further provide insight in the molecular landscape of OL with frequent changes of TP53, FAT1 and NOTCH1. NGS analysis of noninvasively collected samples offers a highly accurate method to detect genetically altered fields in the oral cavity, and predicts development of OSCC in high-risk individuals. Noninvasive genetic screening can be employed to screen high-risk populations for cancer and precancer, map the extension of OL lesions beyond what is visible, map the oral cavity for precancerous changes even when visible abnormalities are absent, test accuracy of promising imaging modalities, monitor interventions and determine genetic progression as well as the natural history of the disease in the human patient. 相似文献
2.
de Souza Gabriel Hernandez Machado Pandolfo Mariana Travi Bortoluzzi Eduardo Antunes da Silveira Teixeira Cleonice Rossetto Hebert Luís da Rosa Amanda Freitas Machado Renata Gondo da Fonseca Roberti Garcia Lucas 《Odontology / the Society of the Nippon Dental University》2022,110(3):535-544
Odontology - The purpose of this study was to investigate whether the root perforation repair with mineral aggregate-based cements affects the retention of customized fiberglass posts to bovine... 相似文献
3.
Malou A.H. Nuijten Thijs M.H. Eijsvogels Valerie M. Monpellier Ignace M.C. Janssen Eric J. Hazebroek Maria T.E. Hopman 《Obesity reviews》2022,23(1):e13370
Postbariatric loss of muscle tissue could negatively affect long-term health due to its role in various bodily processes, such as metabolism and functional capacity. This meta-analysis aimed to unravel time-dependent changes in the magnitude and progress of lean body mass (LBM), fat-free mass (FFM), and skeletal muscle mass (SMM) loss following bariatric surgery. A systematic literature search was conducted in Pubmed, Embase, and Web of Science. Fifty-nine studies assessed LBM (n = 37), FFM (n = 20), or SMM (n = 3) preoperatively and ≥1 time points postsurgery. Random-effects meta-analyses were performed to determine pooled loss per outcome parameter and follow-up time point. At 12-month postsurgery, pooled LBM loss was ?8.13 kg [95%CI ?9.01; ?7.26]. FFM loss and SMM loss were ?8.23 kg [95%CI ?10.74; ?5.73] and ?3.18 kg [95%CI ?5.64; ?0.71], respectively. About 55% of 12-month LBM loss occurred within 3-month postsurgery, followed by a more gradual decrease up to 12 months. Similar patterns were seen for FFM and SMM. In conclusion, >8 kg of LBM and FFM loss was observed within 1-year postsurgery. LBM, FFM, and SMM were predominantly lost within 3-month postsurgery, highlighting that interventions to mitigate such losses should be implemented perioperatively. 相似文献
4.
5.
Rizzo Giuseppe Pietrolucci Maria Elena Capponi Alessandra Mappa Ilenia 《The international journal of cardiovascular imaging》2022,38(5):1017-1019
The International Journal of Cardiovascular Imaging - 相似文献
6.
Laurien J. Zeverijn Eleonora J. Looze Subotheni Thavaneswaran J. Maxime van Berge Henegouwen Robert J. Simes Louisa R. Hoes Katrin M. Sjoquist Hanneke van der Wijngaart Lucille Sebastian Birgit S. Geurts Chee K. Lee Gijsbrecht F. de Wit David Espinoza Paul Roepman Frank P. Lin Anne M. L. Jansen Wendy W. J. de Leng Vincent van der Noort Lindsay V. M. Leek Filip Y. F. L. de Vos Carla M. L. van Herpen Hans Gelderblom Henk M. W. Verheul David M. Thomas Emile E. Voest 《International journal of cancer. Journal international du cancer》2023,153(7):1413-1422
The Dutch Drug Rediscovery Protocol (DRUP) and the Australian Cancer Molecular Screening and Therapeutic (MoST) Program are similar nonrandomized, multidrug, pan-cancer trial platforms that aim to identify signals of clinical activity of molecularly matched targeted therapies or immunotherapies outside their approved indications. Here, we report results for advanced or metastatic cancer patients with tumors harboring cyclin D-CDK4/6 pathway alterations treated with CDK4/6 inhibitors palbociclib or ribociclib. We included adult patients that had therapy-refractory solid malignancies with the following alterations: amplifications of CDK4, CDK6, CCND1, CCND2 or CCND3, or complete loss of CDKN2A or SMARCA4. Within MoST, all patients were treated with palbociclib, whereas in DRUP, palbociclib and ribociclib were assigned to different cohorts (defined by tumor type and alteration). The primary endpoint for this combined analysis was clinical benefit, defined as confirmed objective response or stable disease ≥16 weeks. We treated 139 patients with a broad variety of tumor types; 116 with palbociclib and 23 with ribociclib. In 112 evaluable patients, the objective response rate was 0% and clinical benefit rate at 16 weeks was 15%. Median progression-free survival was 4 months (95% CI: 3-5 months), and median overall survival 5 months (95% CI: 4-6 months). In conclusion, only limited clinical activity of palbociclib and ribociclib monotherapy in patients with pretreated cancers harboring cyclin D-CDK4/6 pathway alterations was observed. Our findings indicate that monotherapy use of palbociclib or ribociclib is not recommended and that merging data of two similar precision oncology trials is feasible. 相似文献
7.
8.
Lesmana Cosmas Rinaldi Adithya Paramitha Maria Satya Gani Rino A. Lesmana Laurentius A. 《Journal of Medical Ultrasonics》2022,49(3):359-370
Journal of Medical Ultrasonics - Chronic liver disease is still a major problem because disease progression will ultimately lead to liver cirrhosis. Portal hypertension is the hallmark in advanced... 相似文献
9.
Kely Paviani StevanatoRaíssa Bocchi PedrosoCatia Millene Dell AgnoloLander Dos SantosFernando Castilho PellosoMaria Dalva de Barros CarvalhoSandra Marisa Pelloso 《Asian Pacific journal of cancer prevention》2022,23(4):1117-1123
Objective: To perform a scoping review of the applicability of the Gail model in different countries for different ethnicities. Methods: The review was conducted based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) checklist and search strategies based on the PICOS approach. The reviewed articles were included if they were published between 2013 and 2018 in English, Portuguese, or Spanish; were original articles available in full online; and described the use of the Gail model. The PubMed, Embase, and Web of Science data bases were searched. Results: A total of 38 articles eligible for analysis were identified, of which 16 used the Gail model to assess breast cancer risk in women, eight analyzed the applicability of this tool in their population, seven compared the tool and/or modified it according to the specific risk factors of their population, and seven cited the model in determining eligibility for chemoprevention. Conclusion: The Gail model has different applicabilities Greater effectiveness and breast cancer risk are found in developed countries. 相似文献
10.
Anne-Sophie Worm Fenger Markus Harboe Olsen Maria Louise Fabritius Christian Gunge Riberholt Kirsten Møller 《Acta anaesthesiologica Scandinavica》2023,67(2):240-247